CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Benzer Materyaller

• SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
  Yazar:: Moyer, Ann M, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
  Yazar:: Dubsky, P., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
  Yazar:: Bartsch, Rupert, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
  Yazar:: Fitzal, F, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
  Yazar:: Gnant, Michael, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)